Il rapporto
Notizie verificate su finanziamenti, sedi centrali e leadership delle aziende più innovative al mondo
44 report e oltre
Harmony Biosciences Appoints Peter Anastasiou President and Chief Executive Officer
Harmony Biosciences appointed Chief Operating Officer Peter Anastasiou as CEO effective January 1, 2027, succeeding retiring CEO Jeffrey M. Dayno, to lead the company’s next phase of growth.
TETRAPHARM Appoints Rolf Sass Sørensen Chief Executive Officer
TETRAPHARM appointed Rolf Sass Sørensen, formerly of Bavarian Nordic, as CEO to succeed co-founder Martin Rose and lead the Danish biopharmaceutical company’s continued development.
Chiesi Appoints David Khougazian Group Chief Executive Officer
Chiesi appointed former Flagship Pioneering executive David Khougazian as Group CEO, succeeding Interim Group CEO Jean-Marc Bellemin, to lead its next phase of innovation-driven growth.
SpyGlass Pharma Opens New Headquarters in Irvine
SpyGlass Pharma opened a 33,000-square-foot headquarters in Irvine, California, on August 27, 2026, moving from its former facility in Aliso Viejo as it prepares for its first product launch.
Collegium Pharmaceutical Plans Headquarters Move to Downtown Boston
Collegium Pharmaceutical plans to move its corporate headquarters from Stoughton to One Lincoln in downtown Boston during the first quarter of 2027.
Apnimed Appoints Kevin R. Lind Chief Executive Officer
Apnimed appointed Board Chair Kevin R. Lind as CEO, succeeding founder Lawrence G. Miller, who will become Vice Chair, as the company builds capabilities toward a potential commercialization of AD109.
BioPharmaceuticals Next Secures $1.6B Series E to Lead Pharmaceuticals Innovation
BioPharmaceuticals Next raises $1.6B in Series E funding at $24.3B valuation to advance 12 drug candidates through clinical trials, scale gene therapy manufacturing, and expand personalized medicine programs.
Seaport Therapeutics Raises $225 Million in Series B - October 21, 2024
Seaport Therapeutics announced $225 Million in Series B funding at a Undisclosed valuation. Seaport Therapeutics is a clinical-stage biopharmaceutical company developing novel therapies for neuropsychiatric disorders using prodrug technology ...
Shire raises $50B Public at $55B valuation
Shire raises $50B in Public at $55B valuation. Biopharmaceutical company...
Visualizzazione di 9 report • Pagina 1 • Categoria: all
Rimani avanti rispetto al mercato
Ricevi insight settimanali nella tua casella di posta. Niente spam, solo intelligenza.